For information on this past event please contact Meetings Management

Friday 14th November 2008

SESSION 9:
THERAPEUTIC ANTIBODES: CANCER
Moderator: Yan Wu (ImClone Systems Inc., USA)

09.00-09.30
‘Anticancer therapeutic antibody targeting cancer cell and tumor-associated activities’
Yan Wu (ImClone Systems Inc., New York, USA)

09.30-10.00
‘A variant IgG1 mediating improved ADCC’
John Lund, Ross Stewart, Michaela Levens, George Thom, Gulin Guler-Gane, Robert Holgate, Chris Gee, Dave Spencer, Carl Webster and Lutz Jermutus (Medimmune Ltd, Cambridge, UK)

10.00-10.30
‘Humanised anti-MUC1 antibody (AS1402) for the treatment of advanced breast cancer’
Nigel Courtenay-Luck (Antisoma Research Ltd, London, UK)

10.30-11.00
Coffee Break & Posters

11.00-11.30
‘Targeting proteases for antibody therapeutic intervention in oncology’
Christopher Scott and Paul J Kerr (Fusion Antibodies, Northern Ireland, UK)

11.30-11.50
‘Development of a potent anti-TYRP1 fully human antibody for melanoma therapy’
Xiaoqiang Kang (ImClone Systems Inc., New York, USA)

11.50-12.20
‘Structured modifications imparting autophilic properties to antibodies’
Fan Gao, Thomas J. Kindt and Christopher A. Lipinski (InNexus Biotechnology Inc., Scottsdale, Arizona, USA)

12.20-12.50
KEYNOTE:
‘Monoclonal antibodies to the T cell receptor (TCRm) in cancer and infectious disease’
Jon Weidanz (Receptor Logic Ltd., Amarillo, Texas, USA)

12.50-14.00
Lunch Break & Posters

SESSION 10:
NEW APPROACHES
Moderator: Mark Glassy (HAH 2008 Conference Chairman)

14.00-14.30
‘Therapeutic cDNA vaccines and disease-specific monoclonal antibodies, which target CD44 on cancer and inflammatory cells’
David Naor (Hebrew University of Jerusalem, Israel)

14.30-14.50
‘New applications for rapid discovery of high value hybridomas and stable therapeutic antibody producing cells using ClonePix FL’
Christopher J. Mann (Genetix Ltd., New Milton, Hampshire, UK)

14.50-15.10
‘The high affinity and potent XOMA 052 anti-IL-1β antibody: designed with a goal in mind’
Linda Masat (XOMA (US) LLC, Berkeley, California, USA)

15.10-15.30
‘VelocImmune: A novel platform for human antibody discovery’
Sean Stevens (Regeneron Pharmaceuticals Inc., Tarrytown, New York , USA)

15.30-16.00
‘Manipulation of T cell populations with cytokine/mAb complexes’
Charles D. Surh (Scripps Research Institute, La Jolla, California, USA)

16.00-16.30
REVIEW:
‘Thirty years of human monoclonal antibodies: past, present and future developments’
Michael Steinitz (The Hebrew University-Hadassah Medical School, Jerusalem, Israel)

Closing Remarks
Mark Glassy (HAH 2008 Conference Chairman)